Today, Strategy Asset Managers LLC Acquires 234,097 Shares of Pfizer Inc. (PFE)

Today, Strategy Asset Managers LLC Acquires 234,097 Shares of Pfizer Inc. (PFE)

Strategy Asset Managers LLC raised its position in shares of Pfizer Inc. (NYSE:PFE) by 367.0% during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 297,887 shares of the biopharmaceutical company’s stock after buying an additional 234,097 shares during the period. Pfizer accounts for 2.4% of Strategy Asset Managers LLC’s portfolio, making the stock its 6th largest position. Strategy Asset Managers LLC’s holdings in Pfizer were worth $10,489,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also bought and sold shares of the stock. City Holding Co. increased its position in shares of Pfizer by 5.5% in the first quarter. City Holding Co. now owns 49,450 shares of the biopharmaceutical company’s stock worth $1,465,000 after buying an additional 2,575 shares during the last quarter. Tompkins Financial Corp increased its position in shares of Pfizer by 0.5% in the first quarter. Tompkins Financial Corp now owns 113,660 shares of the biopharmaceutical company’s stock worth $3,368,000 after buying an additional 588 shares during the last quarter. Raymond James Trust N.A. increased its position in shares of Pfizer by 0.4% in the first quarter. Raymond James Trust N.A. now owns 443,037 shares of the biopharmaceutical company’s stock worth $13,132,000 after buying an additional 1,709 shares during the last quarter. Stokes & Hubbell Capital Management LLC increased its position in shares of Pfizer by 93.6% in the first quarter. Stokes & Hubbell Capital Management LLC now owns 42,534 shares of the biopharmaceutical company’s stock worth $1,261,000 after buying an additional 20,567 shares during the last quarter. Finally, Murphy Pohlad Asset Management LLC increased its position in shares of Pfizer by 12.8% in the first quarter. Murphy Pohlad Asset Management LLC now owns 59,141 shares of the biopharmaceutical company’s stock worth $1,752,000 after buying an additional 6,710 shares during the last quarter. 69.66% of the stock is currently owned by institutional investors and hedge funds.

Shares of Pfizer Inc. (NYSE:PFE) traded up 0.9705% during midday trading on Tuesday, hitting $32.8154. 4,571,398 shares of the company were exchanged. The company has a 50-day moving average price of $33.95 and a 200-day moving average price of $34.35. The stock has a market capitalization of $199.05 billion, a price-to-earnings ratio of 29.0917 and a beta of 0.86. Pfizer Inc. has a 52-week low of $28.25 and a 52-week high of $37.39.

Pfizer (NYSE:PFE) last issued its quarterly earnings results on Tuesday, August 2nd. The biopharmaceutical company reported $0.64 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.62 by $0.02. Pfizer had a return on equity of 23.37% and a net margin of 14.88%. The firm earned $13.10 billion during the quarter, compared to the consensus estimate of $13.01 billion. During the same period last year, the company earned $0.56 earnings per share. The company’s revenue for the quarter was up 10.9% on a year-over-year basis. On average, analysts forecast that Pfizer Inc. will post $2.46 EPS for the current year.

The business also recently declared a quarterly dividend, which will be paid on Thursday, December 1st. Investors of record on Friday, November 11th will be issued a dividend of $0.30 per share. This represents a $1.20 annualized dividend and a dividend yield of 3.69%. The ex-dividend date of this dividend is Tuesday, November 8th. Pfizer’s dividend payout ratio is presently 95.24%.

A number of research analysts have recently issued reports on the stock. Vetr raised shares of Pfizer from a “buy” rating to a “strong-buy” rating and set a $37.42 price objective on the stock in a research report on Monday. Jefferies Group cut shares of Pfizer from a “buy” rating to a “hold” rating and lowered their target price for the stock from $39.00 to $36.00 in a research note on Thursday, October 13th. Argus reiterated a “buy” rating and issued a $39.00 target price on shares of Pfizer in a research note on Tuesday, October 4th. Bank of America Corp. reiterated a “buy” rating and issued a $40.00 target price on shares of Pfizer in a research note on Tuesday, September 27th. Finally, Sanford C. Bernstein reiterated an “outperform” rating on shares of Pfizer in a research note on Monday, September 26th. Eleven analysts have rated the stock with a hold rating, thirteen have given a buy rating and two have issued a strong buy rating to the company. The company currently has a consensus rating of “Buy” and a consensus target price of $38.63.

Pfizer Company Profile

Related posts

Leave a Comment